Investors

Corporate Profile

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. 

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. 

Ongoing clinical studies of imetelstat consist of IMerge™, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS) and IMbark™, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis.

Recent News

Date Title and Summary  
Toggle Summary Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Aug. 22, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of
Toggle Summary Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
MENLO PARK, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
Toggle Summary Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
MENLO PARK, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019 , and recent events. The Company ended the second quarter with $162.3 million in cash and marketable securities.

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com